All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Bookmark this article
The virtual Lymphoma Hub Satellite Symposium at the European School of Haematology (ESH)’s 2nd How to Diagnose and Treat: Lymphoma conference saw a panel of international experts come together to discuss how to manage patients with relapsed and/or refractory (R/R) lymphoma. Kieron Dunleavy, George Washington University Cancer Center, Washington, US, and Marie José Kersten, Amsterdam UMC, Amsterdam, NL, discussed the progress being made in the field of R/R diffuse large B-cell lymphoma (DLBCL). Below you will find their perspectives as presented at the symposium.
The two panelists outlined their approaches to treating a distinct patient case (Figure 1) while highlighting the emerging strategies in the R/R DLBCL setting across Europe and the US.
Figure 1. R/R DLBCL patient case1
ASCT, autologous hematopoietic stem cell transplantation; CAR, chimeric antigen receptor; DHAP, dexamethasone + high-dose cytarabine + cisplatin; DLBCL, diffuse large B-cell lymphoma; ECOG, FISH, fluorescence in situ hybridization; IGHV, immunoglobulin heavy chain variable region; LDH, lactate dehydrogenase; R/R, relapsed and/or refractory; R-CHOP, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone.Kieron Dunleavy began with a summary of what he considers to be feasible next steps for the patient following relapse to chimeric antigen receptor (CAR) T-cell therapy. He outlined recently approved agents and combination regimens, as well as therapies being evaluated in clinical trials. Dunleavy concluded with an emphasis on prognostic techniques, stressing the need for a biopsy to determine the patient’s CD19 expression profile. In terms of therapeutic approach, he suggested enrolling the patient onto a clinical trial evaluating novel bispecific antibodies.
Take part in the survey and watch Kieron Dunleavy’s presentation below.
Welcome to the Lymphoma Hub Satellite Symposium.
Please take a moment to complete the survey and answer the following questions to help us gauge your current understanding of the treatment options available for patients with R/R DLBCL.
Marie José Kersten opened with a comprehensive overview of the pivotal clinical trials evaluating CAR T-cell treatments for DLBCL. She then moved on to explain the most widely understood mechanisms of resistance to CD19-directed CAR T-cell therapy. This introduction helped to paint a clearer picture of the patient case, explaining why a proportion of patients who receive CAR T-cell therapy eventually relapse. Marie José Kersten highlighted the potential benefit of a second infusion of CAR T cells, as was investigated in a cohort of patients from the ZUMA-1 study.
After outlining a number of novel CAR T constructs, she proceeded to discuss non-CAR T-based therapies and relevant clinical trial opportunities for the patient. These included studies evaluating bispecific antibodies, including epcoritamab and blinatumomab, and the CDK9 inhibitor AZD4573.
Kersten also pointed out the discrepancies in access to novel drugs between the US and Europe, and the inter-country variations within Europe.
Watch Marie José Kersten’s presentation below.
Satellite Symposium | Patient with R/R DLBCL— European perspective
Despite the encouraging clinical outcomes demonstrated by CAR T-cell therapies in patients with DLBCL, a proportion of patients do not respond to CAR T-cell therapy, or eventually relapse, as in the selected patient case. There are a number of exciting novel agents in clinical trials that promise to improve the outlook of patients with heavily pretreated DLBCL. Both panelists were in consensus that participation in clinical trials is the optimal approach for managing patients who have exhausted other treatment strategies, including CAR T-cell therapy.
Lymphoma Hub. How I treat relapsed/refractory disease – DLBCL and CLL. Satellite Symposium. ESH How to Diagnose and Treat Lymphoma; Nov 8, 2020; Virtual.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox